Frontiers, Not Boundaries

New MicroMatrices publication: miRNA Biomarkers for Rodent Hepatocarcinogenesis

MicroMatrices are pleased to announce the  publication  of  a landmark paper  entitled “Dose-dependent effects on rat liver miRNAs 200a/b and 429: potential early biomarkers of liver carcinogenesis”. The paper, published this week in Toxicology Reports,  https://www.sciencedirect.com/science/article/pii/S2214750018300842, describes the identification of early  microRNA biomarkers for receptor mediated rodent hepatocarcingenesis, illustrating the principle that retrospective analyses can…

Multiplexed Analytics for In Vitro 3D cultures using SpheroMatrices

SpheroMatrices® spheroid tissue microarray (TMA)  platform preserves  the experimental  layout of your 96 well plate making it possible to compare treatment groups within the same experiment . As the TMA sections are fixed, it is possible to perform Heat-induced Epitope Retrieval (HIER) on  the samples without impacting upon the integrity of the tissue. HIER makes…

MicroMatrices Supports Compound Selection

MicroMatrices supports compound selection in the following ways: SpheroMatrices, a proprietary spheroid tissue microarray technology for de-risking drug safety/efficacy studies. Addressing translatability issues in preclinical drug testing via new analytical processes for profiling 3D organotypic models: spheroids, organoids, PDX 3D models.  Specialist Investigative Toxicology services for risk assessment. Elucidating toxicological/therapeutic mechanisms through the application of…

MicroMatrices Investigative Toxicology Webinar-available on demand

Our webinar entitled “Unlocking the Potential of FFPE Tissues for Investigating Mode of Action of Adverse Outcomes & Improving Predictive Ability” was held Thursday 21 September 2017. We were  joined by scientists from  pharmaceutical and agrochemical companies from the US, Europe, and Japan; we were also pleased to have  EPA registrants attending.   We hope attendees found…

Autumn 2017 Meetings: Liverpool and Berlin

MicroMatrices will be attending two meetings this Autumn. OCTOBER: We will be presenting a poster demonstrating analyses we have made of  3D co-culture neuronal/glioblastoma spheroids at the ELRIG Drug Discovery Meeting  in Liverpool 3-4 October: http://elrig.org/portfolio/drug-discovery-2017-elrigdd17/   NOVEMBER: We are attending BIO-Europe in Berlin 6-8 November . If you will also be attending this meeting…

UNLOCKING MOLECULAR INFORMATION STORED WITHIN FFPE TISSUES FOR MOA, AOPs & BIOMARKERS

PLEASE JOIN US FOR A WEBINAR : UNLOCKING THE POTENTIAL OF FFPE TISSUES FOR INVESTIGATING  MODE OF ACTION OF ADVERSE OUTCOMES & IMPROVING PREDICTIVE CAPABILITY THURSDAY 21 SEPTEMBER: 3PM BST | 4 PM CEST | 10 AM EDT | 7 AM PDT If an adverse outcome, e g  carcinogenicity,  is observed within regulatory safety assessment studies in rodents, the demonstration of…

Bio Conference San Diego 19-22 June

MicroMatrices will be at Bio 2017  in San Diego as part of  the Scottish delegation,  and we invite clients and collaborators to visit us at our stand on the Scottish Pavilion.  Bio (Biotechnology Innovation Organization) is the world’s largest trade association of industry, academia, biotechnology companies, innovators and associated organizations. We look forward to sharing information on…

SpheroMatrices Arrays vs Whole Mount Spheroids

Imaging with SpheroMatrices® offers distinct advantages over competing solutions. Current technologies for imaging 3D spheroids/organoids stain these models in whole mount format, i.e. imaging the whole spheroid. This creates issues with light scattering and fluorescence quenching. Furthermore, only targets on the surface of the  spheroid can be accessed. As a result, imaging of whole mount spheroids…

Rationale for the use of Spheroid Arrays in screening new cancer immunotherapies

  Traditionally the screening of new anti-cancer drugs has relied on in vitro cancer models consisting of  cancer cell lines, where the cytotoxic effects of drugs are screened, and nude mouse xenograft models, where the anti-tumor effects of drugs against human tumor xenografts are tested in vivo. However these models are less  valid when testing the anti-tumour effects of…

SOT 2017: Baltimore, Maryland

MicroMatrices  look forward to meeting clients, colleagues, and collaborators  at this year’s Society of Toxicology meeting in Baltimore, between 12-16 March; we can be found at booth #2569 in the ToxExpo. Once again we will be hosting  a lunch at SOT on Wednesday 15 March. Professor Thomas Hartung (Johns Hopkins University) is our guest  this year and will be making…

WE WORK WITH YOU…

on an interactive, step by step basis. Collaborations can begin with pilot projects which can then be scaled up to larger research programs, according to your requirements.